Oxantel

Oxantel
Clinical data
ATC code	P02CC02 (WHO) QP52AF03 (WHO);
Identifiers
	IUPAC name 3-[(E)-2-(1-Methyl-5,6-dihydro-4H-pyrimidin-2-yl)ethenyl]phenol;
CAS Number	36531-26-7 ;
PubChem CID	5281087;
ChemSpider	4444540 ;
UNII	94AJJ30D9E;
KEGG	D00806 ;
Chemical and physical data
Formula	C13H16N2O
Molar mass	216.28 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCCN=C1/C=C/C2=CC(=CC=C2)O;
	InChI InChI=1S/C13H16N2O/c1-15-9-3-8-14-13(15)7-6-11-4-2-5-12(16)10-11/h2,4-7,10,16H,3,8-9H2,1H3/b7-6+ ; Key:VRYKTHBAWRESFI-VOTSOKGWSA-N ;
(what is this?) (verify)

Oxantel is an anthelmintic. It has typically been used human and animal use as a standard treatment for intestinal worms.

Oxantel is currently being experimented with for the treatment of periodontal disease by the Cooperative Research Centre for Oral Health Science (CRC). Laureate Professor Eric Reynolds AO (former head of the Melbourne Dental School at The University of Melbourne, Australia) and Associate Professor Stuart Dashper are currently testing its ability as a Fumarate reductase inhibitor.

Fumarate reductase is an enzyme that has been found in the pathogenic bacteria in the biofilm in periodontal pockets. This bacteria has the ability to convert blood components into energy and for the bacteria to be virulent. Such bacteria would starve without this enzyme. As such, the role of the Oxantel as a fumarate reductase inhibitor would be to kill the bacteria responsible for periodontal disease.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.